Recently, the number of treatment options for ER+/HER2− advanced breast cancer (ABC) patients has increased due to the expanding knowledge on the biological complexity of breast cancer, which has resulted in better palliative treatment regimens and improved survival [2]. This evidence concerns the gene ESR1 and breast cancer.